QGEN · Qiagen NV
Price
Snapshot
50 fields · last close| Market Cap | $10.32B |
| P/E | 25.05 |
| Float | 205.5M |
| Beta | 0.59 |
| Volatility | 14.8% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 76.9 |
| Price | 50.31 |
| Change | +0.62% |
| Prev Close | 50.00 |
| Open | 48.12 |
| Day Low | 46.89 |
| Day High | 50.25 |
| Avg Vol | 3 |
| Avg $ Vol | $126.2M |
| 52W High | 57.81 |
| 52W Low | 32.53 |
| 52W Pos | 70.3% |
| From High | −12.98% |
| From Low | +54.66% |
| Max DD 1Y | −41.38% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +10.71% |
| SMA 50 | +13.98% |
| SMA 200 | +18.38% |
| RSI (14) | 73.5 |
| Vol 30D | 35.4% |
| Vol 90D | 35.3% |
| 1Y Range | 33–58 |
| Daily bars | 539 |
| Perf Week | +9.75% |
| Perf Month | +14.44% |
| Perf Quarter | +20.63% |
| Perf Half Y | +25.09% |
| Perf Year | +2.73% |
| Perf YTD | +11.33% |
| Prev Day | +0.62% |
| Clavix | B+ |
| Debt / Eq | 0.44 |
| Curr Ratio | 3.90 |
| Int Cover | 507.1× |
| FCF Margin | 21.3% |
| Rev Growth | +0.3% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 6 / 19 |
Clavix risk grade
regraded every trading dayQGEN grades B+, 76.9 of 100. Steadiest on Macro Resilience (68), most exposed on Price Stability (58, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 6 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| QGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.59 | 1.18 |
| Volatilityannualized | 14.8% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −41.4% | — |
| Typical daily movemedian absolute daily change | 1.00% | — |
| Days beyond ±3%of the last 252 sessions | 21 (8%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| QGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.59 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| QGEN | |
|---|---|
| 1 week | +9.7% |
| 1 month | +14.4% |
| Year to date | +11.3% |
| 1 year | +2.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| QGEN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 10 Aug |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 0 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| QGEN | |
|---|---|
| Revenue growthyear over year | +0.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openQIAGEN and the EQT XI fund agreed that Crown NL Bidco B.V., indirectly controlled by EQT, will make a recommended voluntary takeover offer for all outstanding QIAGEN shares at €46.50 per share in cash. The excerpt does not state that the offer has closed or provide its conditions and timetable.
Bloomberg News reported, citing people familiar with the matter, that Qiagen is in advanced talks to be acquired by Swedish private-equity firm EQT. No price, timeline or signed agreement was disclosed.
QIAGEN will host a Global TB Clinical and Educational Summit on October 13-16, bringing together tuberculosis experts as the WHO warns that funding reductions could threaten TB prevention, diagnostics, and treatment. The company highlighted that its QuantiFERON-TB test has sold more than 160 million units worldwide and is used in over 130 countries, positioning it as a key screening tool to identify people eligible for preventive treatment.
QIAGEN announced new artificial intelligence tools to help researchers analyze complex biological and genomic data faster, including IPA Investigator (an AI research companion for its Ingenuity Pathway Analysis software) and the new QIAGEN Discovery Platform. The article body is truncated, so additional details are not available.
QIAGEN announced new AI tools to help researchers analyze complex biological and genomic data faster while keeping the underlying evidence visible. The expansion includes IPA Investigator, an AI companion for its existing Ingenuity Pathway Analysis software, and a new QIAGEN Discovery Platform (article text was truncated).
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TXG | 10X Genomics Inc | C- | $9.85B | — | 2.01 | Compare |
| TECH | Bio-Techne Corp | B | $11.39B | 62.59 | 1.29 | Compare |
| RGEN | Repligen Corp | B- | $11.43B | 279.84 | 1.13 | Compare |
| AVTR | Avantor Inc | B- | $11.67B | — | 0.98 | Compare |
| BRKR | Bruker Corp | C | $9.01B | — | 1.24 | Compare |
| TEM | Tempus AI Inc | D- | $12.23B | — | 2.54 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $16.46B | — | 1.38 | Compare |
| RVTY | Revvity Inc | B | $17.48B | 74.16 | 1.09 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.